Jasper Therapeutics
Logotype for Jasper Therapeutics Inc

Jasper Therapeutics (JSPR) investor relations material

Jasper Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Jasper Therapeutics Inc
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • Q3 net loss was $144.5m, including a $129.5m acquired IPR&D charge; $8.0m of Mirador drug-supply revenue was offset by $8.0m in related costs.

  • July acquisition of Kira expanded the pipeline with KP104, KP701 and discovery-stage complement programs; the portfolio also includes briquilimab and vensobafusp alfa.

Financial highlights

  • Q3 revenue was $8.0m, operating loss was $144.2m and net loss was $144.5m, versus $18.7m net loss in Q3 2025.

  • 9M revenue was $8.0m, operating loss was $164.3m and net loss was $148.4m, versus $66.7m net loss in 9M 2025.

  • Q3 R&D expense fell 42% YoY to $8.3m and G&A rose 33% to $6.4m; 9M R&D fell 63% to $19.3m and G&A fell 4% to $15.6m.

  • Cash and cash equivalents were $135.3m at Sept. 30, 2026, versus $28.7m at Dec. 31, 2025; accumulated deficit was $465.1m.

Outlook and guidance

  • KP104 interim IgAN Stage 1 data expected Q4 2026, with updated data in Q1 2027; initial C3G/IC-MPGN data expected Q2 2027 and FSGS data Q3 2027.

  • First FSGS expansion-cohort patients expected to be dosed Q1 2027; initial briquilimab SCID conditioning study data expected Q4 2026, with SCID pre-BLA meeting next steps expected Q1 2027.

  • KP104 pre-IND meeting next steps for PNH expected H1 2027; a new indication announcement is anticipated by end-2026. KP701 CTA or IND filing expected Q1 2027 and first-in-human data Q3 2027.

  • Discovery-stage complement candidate selection expected mid-2027; R&D expense expected to increase substantially as programs advance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
Jasper Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutic agents primarily for hematopoietic stem cell transplantation and gene therapies. The company is focused on advancing novel therapeutic agents intended for a variety of applications, including conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes. Additionally, Jasper Therapeutics is developing new conditioning regimens for stem cell transplantation and ex-vivo gene therapy, which involves the genetic manipulation of cells outside the body before transplantation. Their leading product candidate, briquilimab, is designed to clear hematopoietic stem cells from bone marrow to facilitate allogeneic stem cell or gene therapy. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.